Stealth BioTherapeutics Corp. (NASDAQ:MITO) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.02 per share.
For the full year, analysts predict loss of $ 0.09 per share.
Stock Performance
Shares of Stealth BioTherapeutics Corp. traded up $ 0.04 or 2.92 percent on Wednesday, reaching $ 1.41 with volume of 19.60 thousand shares. Stealth BioTherapeutics Corp. has traded high as $ 1.43 and has cracked $ 1.37 on the downward trend
The closing price of $ 1.41, representing a 52.22 % increase from the 52 week low of $ 0.90 and a 90.49 % decrease over the 52 week high of $ 14.41.
The company has a market capital of $ 69.93 million and is part of the Healthcare sector and Biotechnology industry.
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The companys product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis.
